Pharma giant AstraZeneca and Oxford University on Saturday, September 12, said they had resumed a COVID-19 vaccine trial after getting the all-clear from British regulators, following a pause caused by a UK volunteer falling ill.
An independent committee was drafted in to review safety, in what the company and the World Health Organization described as a routine step. After the pause, AstraZeneca had said it remained hopeful that the vaccine could still be available"by the end of this year, early next year". Charlotte Summers, lecturer in intensive care medicine at Cambridge University, welcomed the resumption of the Oxford trial and said the researchers had shown their commitment"to putting safety at the heart of their development programme."
The AZD1222 vaccine uses a weakened version of a common cold-causing adenovirus engineered to code for the spike protein that the COVID-19 coronavirus uses to invade cells. "The company will continue to work with health authorities across the world and be guided as to when other clinical trials can resume to provide the vaccine broadly, equitably and at no profit during this pandemic."
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: manilabulletin - 🏆 25. / 51 Read more »